The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

van Zonneveld, M; Flink, HJ; Verhey, E; Senturk, HAKAN; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMK; Gerken, G; de Man, RA; Hansen, BE; Schalm, SW; Janssen, HLA

doi:10.1111/j.1365-2036.2005.02453.x

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

Atıf İçin Kopyala

van Zonneveld M., Flink H., Verhey E., Senturk H. , Zeuzem S., Akarca U., ...Daha Fazla

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, cilt.21, sa.9, ss.1163-1171, 2005 (SCI İndekslerine Giren Dergi)

Cilt numarası: 21 Konu: 9
Basım Tarihi: 2005
Doi Numarası: 10.1111/j.1365-2036.2005.02453.x
Dergi Adı: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Sayfa Sayıları: ss.1163-1171

Özet

Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.